BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses 
Google Disrupts Major Residential Proxy Network IPIDEA 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
The Maire - EuroChem Case: Three Lessons for Global Business 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
C3.ai in Merger Talks With Automation Anywhere as AI Software Industry Sees Consolidation 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
SAN DIEGO, May 22, 2017 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that Andy Rasdal, Chief Executive Officer of Obalon, and William Plovanic, Chief Financial Officer of Obalon, will present at the following investor conference:
- UBS Global Healthcare Conference
Tuesday, May 23, 2017, Presentation at 1:00pm EST
Grand Hyatt, New York, NY
Webcast Available at:
https://cc.talkpoint.com/ubsx001/052217a_as/?entity=88_Q55L3I5
Live audio webcasts of the presentation can be accessed through the link above. Replays of the webcasts will be available for 90 days following each presentation.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
For Obalon Therapeutics, Inc. Investor Contact: William Plovanic Chief Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103 [email protected] Media: Megan Driscoll EvolveMKD Office: +1 646 517 4220 [email protected]
